211 related articles for article (PubMed ID: 32277868)
1. Switching protease inhibitors to rilpivirine in HIV-positive individuals with complete viral suppression and without prior HIV drug resistance in a resource-limited setting: a randomized controlled trial.
Palanuphap K; Sungkanuparph S
J Int AIDS Soc; 2020 Apr; 23(4):e25462. PubMed ID: 32277868
[TBL] [Abstract][Full Text] [Related]
2. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
Gatechompol S; Avihingsanon A; Apornpong T; Han WM; Kerr SJ; Ruxrungtham K
AIDS Res Ther; 2019 Apr; 16(1):7. PubMed ID: 30953533
[TBL] [Abstract][Full Text] [Related]
4. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
Ho S; Wong JG; Ng OT; Lee CC; Leo YS; Lye DCB; Wong CS
AIDS Res Ther; 2020 May; 17(1):23. PubMed ID: 32438914
[TBL] [Abstract][Full Text] [Related]
6. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
[TBL] [Abstract][Full Text] [Related]
7. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
[TBL] [Abstract][Full Text] [Related]
9. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
10. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
11. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
[TBL] [Abstract][Full Text] [Related]
12. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
[TBL] [Abstract][Full Text] [Related]
13. Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
Phongsamart W; Jantarabenjakul W; Chantaratin S; Anugulruengkitt S; Suntarattiwong P; Sirikutt P; Kosalaraksa P; Maleesatharn A; Chokephaibulkit K
J Int AIDS Soc; 2022 Jan; 25(1):e25862. PubMed ID: 35001501
[TBL] [Abstract][Full Text] [Related]
14. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
[TBL] [Abstract][Full Text] [Related]
15. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz CR; Johnston S; Romeu J; Lange J; Clotet B;
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):229-36. PubMed ID: 11464141
[TBL] [Abstract][Full Text] [Related]
17. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
[TBL] [Abstract][Full Text] [Related]
18. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
[TBL] [Abstract][Full Text] [Related]
19. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
20. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.
Negredo E; Estrada V; Domingo P; Gutiérrez MD; Mateo GM; Puig J; Bonjoch A; Ornelas A; Echeverría P; Estany C; Toro J; Clotet B
J Antimicrob Chemother; 2017 Mar; 72(3):844-849. PubMed ID: 27999056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]